The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Phase I trial results for oral azacitidine and venetoclax in R/R AML
Maria Amaya, MD, PhD, University of Colorado School of Medicine, Aurora, CO, shares the results from the Phase I dose escalation study investigating treatment of relapsed/refractory acute myeloid leukemia (R/R AML) using oral azacitidine and venetoclax (NCT05287568) in two cohorts taking either 200 or 300mg of oral azacitidine for 14 days followed by venetoclax. Dr Amaya explains that the regimens were well tolerated, comparable to intravenous azacitidine and venetoclax, and resulted in only low-grade toxicities. Dr Amaya then discusses the current state of the trial in terms of patient response, suggesting the regimen has promising activity in the R/R AML setting. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
